Pliant Therapeutics Rises $1.25 Ahead of ASCO Conference
Pliant Therapeutics shares rose 1.2% to $1.25 in late trading Thursday, with volume over 210,000 shares and a market cap near $77 million. The move came ahead of new data set for release May 30 at ASCO from the Phase 1b FORTIFY trial of PLN-101095 in checkpoint-inhibitor-refractory solid tumors. Pliant reported a Q1 net loss of $20 million and held $172.4 million in cash as of March 31.